

Regulated information

Publication related to a transparency notification

(article 14, subparagraph 1 of the law of 2 May 2007 regarding the disclosure of important shareholdings in listed companies)

Brussels, Belgium, 7 January 2019, 5.45 pm (CET) – ASIT biotech (ASIT - BE0974289218), a clinical stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough immunotherapy products for the treatment of allergies, today announces that it has received a transparency notification dated 4 January, 2019, the result of which is - as a result of which people don't act anymore in concert and the threshold of participation of 5% isn't crossed anymore.

The statement dated 4 January 2019 notably includes the following information:

- **Purpose of the notification**

End of a concerted action agreement

- **Notification by**

People acting in concert

- **Person subject to the notification requirement**

Chagral Invest SPRL : 523, Avenue Louise – 1050 Bruxelles
3T Finance SA : 6B bt7, Avenue Lloyd George – 1000 Bruxelles

- **Date of the transaction**

December 27th, 2018

- **Threshold crossed (%)**

The threshold of 5% is crossed

- **Denominator**

A total of 18,396,848 voting rights

- **Details of the notification**

A) Voting rights	Previous notification	After the transaction			
		# voting rights		% of voting rights	
Holders of voting rights		Attached to shares	<u>Non-attached to shares</u>	Attached to shares	<u>Non-attached to shares</u>
CHAGRAL INVEST SPRL		406,913		2.21%	
3T FINANCE SA		671,074		3.65%	
Sub-total					
	TOTAL				

- **Chain of controlled companies through which the participation is actually held**

CHAGRAL INVEST and 3T FINANCE SA are not controlled within the meaning of Articles 5 and 7 of the Company Code

- **This notification is available on ASIT biotech’s website, in the Documentation / Regulated information section:**

<https://www.asitbiotech.com/investors/documentation>

About ASIT biotech

ASIT biotech is a Belgian clinical stage biopharmaceutical company focused on the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies. Thanks to its innovative ASIT+™ technology platform, ASIT biotech is currently the only developer of allergy immunotherapy (AIT) product candidates consisting of a unique mixture of highly purified natural allergen fragments in an optimal size selection. This innovation results in a short treatment, expected to improve patient compliance and real-life effectiveness. ASIT biotech’s product pipeline contains three novel ASIT+™ product candidates targeting respiratory allergies with the highest prevalence (i.e. grass pollen: gp-ASIT+™ and house dust mite: hdm-ASIT+™), and food allergies (peanut allergy: pnt-ASIT+™) that could significantly expand the current immunotherapy market. The Company believes that its innovative ASIT+™ platform is flexible and would be applicable across a range of allergies.

ASIT biotech has a headcount of 26 staff members, at its headquarters in Brussels and a laboratory in Liège, Belgium.

Further information can be found at www.asitbiotech.com.

Contacts

Company

Michel Baijot, Managing Director
ASIT biotech
Tel.: +32 2 264 03 90
investors@asitbiotech.com

Media and Investor Relations - France

NewCap
Dusan Oresansky / Pierre Laurent
Tel.: +33 1 44 71 94 92
asitbiotech@newcap.eu



Media Relations - Belgium

Laure-Eve Monfort
Tel.: +32 2 290 90 93
monfort@comfi.be